DocGo AI Stock Analysis
Want to see DCGO full AI Analyst Report?
DocGo (DCGO) AI Stock Analysis
DocGo
(NASDAQ:DCGO)
The score is held down primarily by weak financial performance (significant recent losses and negative TTM cash flow) and bearish technicals (price below all key moving averages with negative MACD). The earnings call provides partial support due to improving operating metrics and an articulated path toward 2027 EBITDA positivity, but near-term guidance still implies losses and cash pressure, limiting the overall rating.
DocGo (DCGO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $16.99M
- Dividend Yield
- ―
- Average Volume (3M)
- 721.43K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.67
- Revenue Growth
- -19.22%
- EPS Growth
- -254.04%
- Country
- US
- Employees
- 3,568
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
DocGo Business Overview & Revenue Model
Company Description
DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical emer...
DocGo Earnings Call Summary
The call was broadly constructive, with substantial sequential improvement in adjusted EBITDA, gross margin, SG&A, transportation revenue, non-migrant Mobile Health growth, and operating efficiency. Management also outlined a path toward positive adjusted EBITDA in 2027 and continued progress on portfolio optimization. However, the company remains loss-making, reduced 2026 revenue guidance, reported declining cash, faced lower Mobile Health margins and elevated fuel costs, and is managing a CEO transition. Overall, the number and significance of the operational improvements outweighed the disclosed challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
DocGo reaffirmed full year 2026 adjusted EBITDA guidance of a loss of $17 million-$22 million and revised revenue guidance to approximately $300 million, excluding any revenue from Hicuity Health; fourth-quarter revenue is expected to be somewhere in the $77 million, $78 million range or something like that, which management said looks very achievable. Medical transportation is expected to contribute about $205 million or so to $210 million, remote patient monitoring $16 million-$17 million, SteadyMD between $30 million and $35 million, mobile phlebotomy between $5 million and $6 million, clinical staffing about $14 million, $15 million, and Care in the Home probably $7 million or $8 million, maybe even as much as $9 million. For 2027, the company specifically did not issue guidance, but expects some solid revenue gains year-over-year, medical transportation growth at a high single-digit level, a little bit more moderated growth in Care in the Home, and some positive adjusted EBITDA for the full year; management also said positive operating cash flow might occur in Q1 or maybe even Q2.
DocGo Financial Statement Overview
Summary
Overall fundamentals are pressured by a sharp swing to significant losses (2025 and TTM) and negative EBITDA, despite relatively steady gross margins in the low-to-mid 30% range. The balance sheet leverage appears manageable (modest debt-to-equity), but cash flow has been volatile with negative operating and free cash flow in the latest TTM, increasing near-term funding and execution risk.
Income Statement
24NegativeBalance Sheet
56NeutralCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 297.34M | 322.20M | 616.56M | 624.29M | 440.52M | 318.72M |
| Gross Profit | 95.12M | 98.76M | 213.57M | 195.38M | 154.72M | 109.75M |
| EBITDA | 2.64T | -170.82M | 45.56M | 32.73M | 33.35M | 27.63M |
| Net Income | -181.25M | -182.40M | 19.99M | 6.86M | 34.58M | 23.74M |
Balance Sheet | ||||||
| Total Assets | 173.90M | 217.10M | 455.62M | 490.45M | 393.28M | 309.60M |
| Cash, Cash Equivalents and Short-Term Investments | 19.11M | 51.02M | 89.24M | 59.29M | 157.34M | 175.54M |
| Total Debt | 24.64M | 29.18M | 57.19M | 46.50M | 19.91M | 16.51M |
| Total Liabilities | 94.92M | 91.23M | 140.44M | 185.28M | 114.35M | 82.55M |
| Stockholders Equity | 105.08M | 144.01M | 320.92M | 300.79M | 273.23M | 219.58M |
Cash Flow | ||||||
| Free Cash Flow | -30.99M | 27.02M | 64.50M | -74.35M | 23.37M | -8.60M |
| Operating Cash Flow | -27.99M | 34.45M | 70.34M | -64.22M | 28.87M | -1.95M |
| Investing Cash Flow | -16.47M | -39.08M | -10.87M | -29.88M | -38.45M | -8.59M |
| Financing Cash Flow | -9.09M | -50.82M | -24.15M | 1.12M | -6.18M | 155.21M |
DocGo Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCGO, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.30, and below the 200-day MA of 0.53, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 29.60 is Positive, neither overbought nor oversold. The STOCH value of 4.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCGO.
DocGo Risk Analysis
DocGo disclosed 72 risk factors in its most recent earnings report. DocGo reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksDocGo Peers Comparison
Overall Rating
ADUS83Outperform
VMD75Outperform
AVAH65Neutral
DCGO46Neutral
MNDR43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | $2.26B | 20.18 | 9.81% | ― | 11.53% | 27.72% | |
| 75Outperform | $326.26M | 21.14 | 10.78% | ― | 21.81% | 17.67% | |
| 65Neutral | $2.34B | 7.28 | 115.53% | ― | 16.84% | 280.13% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $16.99M | -0.09 | -144.87% | ― | -19.22% | -254.04% | |
| 43Neutral | $1.13M | -0.04 | -27.32% | ― | 4.47% | 92.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DCGO | DocGo, Inc. | 0.17 | -0.80 | -82.33% | |
| ADUS | Addus HomeCare Corporation | 121.07 | 8.37 | 7.43% | |
| VMD | Viemed Healthcare US | 8.61 | 1.95 | 29.28% | |
| AVAH | Aveanna Healthcare Holdings Inc | 10.70 | 1.96 | 22.43% | |
| EUDA | Euda Health Holdings Limited | 17.37 | -39.23 | -69.31% | |
| MNDR | Mobile-health Network Solutions Class A | 0.95 | -27.55 | -96.68% |
DocGo Corporate Events
DocGo Announces CEO Transition and Separation Agreement
NeutralDocGo Inc. said on November 13, 2026, that it had entered into a Transition Services and Separation Agreement with CEO Lee Bienstock as it searches for a successor before his employment agreement expires on December 31, 2026. The agreement provides f...
DocGo Secures New Credit Facility and Warrant Financing
NeutralOn October 1, 2026, DocGo and subsidiaries Hicuity and Ambulnz entered into an amended and restated credit agreement and guaranty that refinances existing debt and adds new term loan facilities totaling up to $102 million, maturing on December 6, 202...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
